Chlamydia pneumoniae is a major cause of acute respiratory tract disease in humans and has been responsible for both endemic and epidemic pneumonia (5) . In addition, this organism has been associated with other clinical manifestations, including coronary artery disease, asthma, and sarcoidosis (7, 8, 16, 18) . The finding that 50 to 60% of adults in the diverse geographical places studied have serological evidence of C. pneumoniae infection makes this one of the most prevalent infectious agents (5, 19) . Two serodiagnostic tests have been used routinely for C. pneumoniae, the microimmunofluorescence test and the complement fixation test (5, 19) . The microimmunofluorescence test is specific for C. pneumoniae; the complement fixation test measures cross-reactive antibodies against the genus Chiamydia. Because C. pneumoniae immunoglobulin G (IgG) antibody persists for long time periods and, in reinfection, IgM or complement fixation antibody is often absent, differentiation of reinfection from previous infections is difficult (5) . The difficulty in isolating and/or demonstrating the presence of the organisms has made epidemiological studies of transmission, host range, tissue tropism, and association of the organism with specific clinical manifestations more difficult.
The development of the polymerase chain reaction (PCR) has provided-an alternative diagnostic method for etiological agents that are difficult to culture or detect (15) . This method has been used successfully for the detection of Chlamydia trachomatis DNA in clinical samples (3, 9, 14) . By using primers that recognized conserved sequences on Chlamydia major outer membrane protein genes or the 60-kDa cysteinerich protein, PCR has been used for differentiation of Chlamydia spp. (9, 20) . In this article, we report the DNA amplification of C. pneumoniae-specific sequences by PCR for direct detection of C. pneumoniae. 
MATERIALS AND METHODS
Isolates. C. pneumoniae isolates used in this study included the following: TW-183 (the prototype strain isolated in 1965 in Taiwan); AR-39, AR-277, AR-388, AR-458, and LR-65 (isolated in Seattle, Washington); KA-5C (isolated by P. Saikku in Finland); AC-43 (isolated by T. Yamazaki in Japan); 2023 (isolated by M. Hammerschlag in New York, N.Y.); and CWL-29 and CWL-50 (isolated by the Centers for Disease Control, Atlanta, Ga.). All C. pneumoniae isolates except TW-183 were from the respiratory tract. TW-183 was obtained from the conjunctiva of a child. The C. trachomatis serovars used included B/TW-5/OT, C/TW-3/ OT, D/UW-3/Cx, E/UW-5/Cx, F/UW-6/Cx, H/UW-4/Cx, I/UW-12/Ur, and L2/434/Bu. The Chlamydia psittaci strains included guinea pig inclusion conjunctivitis (GPIC), feline pneumonitis (FP), meningopneumonitis (Mn), ovine abortion (OA), and 6BC. 6BC is an avian psittacosis strain. The other strains were of mammalian origin. All chlamydial strains were previously described (2) . Other bacteria used in this study were Table 1 .
Growth and purification of organism. All chlamydial strains listed above were adapted to grow in a HeLa-229 cell culture (12) . Subsequently, C. pneumoniae isolates were grown in HL cells as previously described (11 Clinical samples. The clinical samples used were from past and current studies of acute respiratory tract infection with C. pneumoniae (6) and sexually transmitted diseases due to C. trachomatis (1) . The throat and urethral swabs were eluted in 1 ml of chlamydia transport medium containing sucrose and glutamic acid in potassium phosphate buffer. Lung tissue from which C. psittaci was isolated came from an adult male who died of pneumonia; the tissue was sent to us for diagnosis by H. Dowda, South Carolina Department of Health and Environmental Control, Columbia. For all clinical specimens, serodiagnosis of C. pneumoniae was done by using the microimmunofluorescence test (19 Dot blot analysis. To test reactivity of the 474-bp restriction fragment with purified chromosomal DNA, 0.1 to 1 ,ug of DNA was added per well. For analysis of PCR products with the C. pneumoniae 474-bp fragment as the probe, 10 to 30 RI of the reaction product was added per well. Samples were boiled for 10 min in 0.3 M NaCl, and 2.0 M ammonium acetate was added to a final volume of 400 ,ul. Samples were applied either to nitrocellulose (Trans-Blot; Bio-Rad Laboratories, Richmond, Calif.) or to nylon (Zeta-Bind, for analysis of PCR products; Bio-Rad) with a Bio-Dot microfiltration apparatus (Bio-Rad) according to the directions of the manufacturer. Filters were baked at 80°C for 2 h prior to hybridization.
Hybridizations. Probe DNA was labeled by using the multi-prime labeling kit (Amersham, Arlington Heights, Ill.) according to the directions of the manufacturer. Generally, 3 x 106 cpm was added per hybridization. The hybridization reaction buffer included 50% formamide, 5 x Denhardt's reagent, 5x SSPE (1x SSPE is 180 mM NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.4]), 10 ,ug of salmon sperm DNA per ml, and 0.1% sodium dodecyl sulfate. After hybridization for 18 h at 42°C, three washes were done in 0.lx SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and 0.1% sodium dodecyl sulfate for 15 min each at 52°C followed by three washes with 0.1x SSC.
DNA sequence analysis. The Sanger dideoxy-chain termination method of DNA sequencing (17) was carried out on single-stranded fragments cloned into M13mpl8 by using a Sequenase kit (United States Biochemical Corp., Cleveland, Ohio). Nested deletions were generated by using the Erasea-Base kit (Promega, Madison, Wis.). Sequence analyses were performed by the Pustell sequence analysis program (IBI) and the University of Wisconsin Genetics Computer Group programs.
PCR. The nucleotide sequences of the different primers (from the 5' to 3' end) are as follows: HL-1, GTTGTTCA TGAAGGCCTACT; HM-1, GTGTCATTCGCCAAGGTT AA; and HR-1, TGCATAACCTACGGTGTGTT. Samples were amplified for 40 cycles. Each cycle consisted of the following: denaturation at 94°C for 1 min, annealing (temperature varied depending on the primer set [see Results]) for 1 min, and primer extension at 72°C for 1 min. The buffers and reagents used were those supplied in the GeneAmp kit (Perkin-Elmer Cetus, Norwalk, Conn.). Amplification products were analyzed by electrophoresis through a 1.5% agarose gel by standard methods (13) .
For optimization of the PCR conditions, the optimal annealing temperature and concentrations of the different PCR components were chosen as those giving the greatest yield of amplification product without any nonspecific amplification. For (Fig. 2) . None of the C. trachomatis or C. psittaci strains tested were amplified by either primer pair. To ensure that the amplified products of the expected size represented the target sequence, the products were digested with restriction enzymes known to cut within the target sequence. The 229-and 437-bp amplification products were digested with AccI and DdeI (data not shown). Cleavage of the HL-1-HR-1 amplification product with AccI yielded the expected 207-and 230-bp fragments. Digestion with DdeI produced the expected 195-and 242-bp fragments. For the HM-1-HL-1 amplification product, cleavage with AccI resulted in 22-and 207-bp fragments; digestion with DdeI yielded 34-and 195-bp fragments. Both amplification products were recognized in dot blot hybridization when the radiolabeled C. pneumoniae 474-bp fragment was used as the probe (data not shown).
The ability of the C. pneumoniae-derived primers to amplify normal flora and pathogens found in the respiratory tract was tested. None of the bacteria listed in Table 1 was amplified by either primer pair.
Optimization of reaction conditions. Several parameters were varied for each primer set to obtain optimal reaction conditions. Annealing temperatures of 37, 42, 48, 55, and 60°C were tested. The following MgCl2, primer, and oligonucleotide concentrations were analyzed in all possible combinations: MgCI2, 1 to 10 mM; primers, 0.2, 0.5, 1.0, and 2.0 ,uM; and, oligonucleotides, 20, 50, 100, and 200 R,M. The parameters that resulted in maximum amplification for each primer set were as follows: for HL-1-HR-1, 55°C, 1 U of Taq polymerase, 5 mM MgCl2, 50 ,M deoxynucleoside triphosphates (dNTPs), and 0.5 ,uM primer; for HM-1-HR-1, 48°C, 1 U of Taq polymerase, 3 mM MgCl2 200 ,uM dNTPs, and 0.5 ,uM primer.
By using the parameters determined for each primer set, chlamydial organisms for which the number of IFUs per milliliter had been determined were tested in various dilutions to determine detection limits of amplification products. As shown in Fig. 3 , the HM-1-HR-1 primer pair detected fewer IFUs than the HL-1-HR-1 primer pair. Both primer sets detected less than 1 IFU.
Detection of C. pneumoniae in clinical specimens. Throat specimens were tested from patients that were seropositive and isolation positive (one to nine inclusions were observed per cell monolayer on a 12-mm-diameter coverslip) for C. pneumoniae (n = 8), seropositive and isolation negative for C. pneumoniae (n = 8), and seronegative and isolation negative for C. pneumoniae (n = 20). In addition, urethral or cervical samples from patients with proven C. trachomatis infection and a lung specimen from a patient from whom C. psittaci was isolated were also tested. In initial experiments shown in Fig. 4 , throat specimens from patients from whom C. pneumoniae was isolated (isolates AR-1130, AR-1140, and AR-1150) and a seropositive patient from whom the organism (AR-1128) was not isolated were amplified by PCR by using the C. pneumoniae-specific primers. In contrast, no amplification product was observed in the seronegative and isolation-negative specimens (AR-1129 and AR-1141) or in specimens from patients with known C. trachomatis infections or from a patient with a C. psittaci infection. Of those tested, 8 of 8 seropositive and isolation-positive samples were positive by PCR, 4 of 8 seropositive and isolationnegative samples were PCR positive, and none of the 20 seronegative samples were amplified by C. pneumoniae primers. All of the PCR-positive specimens were amplified by both primer pairs. None of the four specimens from C. trachomatis or C. psittaci patients were amplified by these primers. All PCR-positive specimens yielded products that were detected by agarose gel electrophoresis and were confirmed by dot blot hybridization. All PCR-negative reactions were also negative by dot blot.
DISCUSSION
Primers complementary to sequences on a C. pneumoniae 474-bp Pstl fragment were identified for use in PCR for detection of C. pneumoniae. By using the optimal reaction conditions determined for each primer pair, specific amplification of C. pneumoniae was achieved. All C. pneumoniae isolates tested from different geographical locations were amplified by PCR; however, C. trachomatis, C. psittaci, and other organisms tested were not amplified by either primer pair. Thus, these results suggest that this method should provide an alternative method to immunofluorescence (6) In the studies reported in this article, the appropriate concentration of clinical specimen to use for amplification differed among the specimens. In most cases, amplification could be achieved by concentrating 50 to 300 ,ul of sample and resuspending it in lysis buffer. However, in some cases, concentration resulted in inhibition of the PCR, presumably because of inhibitors of the Taq polymerase that were present in the clinical samples. In these cases, dilution of the sample specimens or DNA purification circumvented the inhibition. Further studies are needed to define the best method for preparation of clinical specimens, and a larger number of specimens should be tested to determine sensitivity and specificity. However, the results suggest that the C. pneumoniae-specific primers should prove valuable for diagnosis and application to epidemiological studies.
